Hofseth BioCare (HBC.OL) Stock Analysis & AI Equity Report
Hofseth BioCare (HBC.OL) overview
Hofseth BioCare (HBC.OL) stock analysis and AI equity research. For the latest completed financial year, 2024, Hofseth BioCare reported revenue of NOK 257m and operating profit of NOK -114m; the year-end share price was 1.70 NOK and market capitalisation was NOK 699m. Hofseth BioCare is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Hofseth BioCare's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-12-12. Data will be refreshed during report generation.
About Hofseth BioCare
Hofseth BioCare ASA is a Norwegian biotechnology and consumer health company that processes salmon side streams into marine ingredients for human and pet nutrition. Its main products include salmon oil, protein and peptide ingredients, and calcium-rich bone powder. The company also develops and commercializes these ingredients through research, processing and sales activities.
Generate the Hofseth BioCare report
Hofseth BioCare is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Hofseth BioCare and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.